Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives
Journal of Clinical Medicine · 12.07.2023 · 12 (14) · 4646
DOI: 10.3390/jcm12144646 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 12.07.2023. Verfasst von Yasushi Sato und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Medicine for Gastroenterology and Oncology, Tokushima University Graduate School of Medical Science, Tokushima 770-8503, Japa…. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gastric cancer is a heterogeneous disease with diverse histological and genomic subtypes, making it difficult to demonstrate treatment efficacy in clinical trials. However, recent efforts have been made to identify molecular biomarkers with prognostic and predictive implications to better understand the broad heterogeneity of gastric cancer and develop effective targeted therapies for it. HER2 overexpression, HER2/neu amplification, MSI-H, and PD-L1+ are predictive biomarkers in gastric cancer, and a growing number of clinical trials based on novel biomarkers have demonstrated the efficacy of targeted therapies alone or in combination with conventional chemotherapy. Enrichment design clinical trials of targeted therapies against FGFR2b and claudin 18.2 have demonstrated efficacy in unresectable advanced gastric cancer. Nonetheless, it is essential to continuously validate promising molecular biomarkers and introduce them into clinical practice to optimize treatment selection and improve patient outcomes. In this review, we focused on established (PD-L1, HER2, MSI) and emerging biomarkers (FGFR2, CLDN18.2) in gastric cancer, their clinical significance, detection methods, limitations, and molecular agents that target these biomarkers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Community Medicine for Gastroenterology and Oncology, Tokushima University Graduate School of Medical Science, Tokushima 770-8503, Japan.
- Department of Gastroenterology and Oncology, Tokushima University Graduate School of Medical Science, Tokushima 770-8503, Japan.
- Department of Gastroenterology, Hokkaido Cancer Center, Sapporo 060-0042, Japan.
ORCID-Profile: Yasushi Sato, Yutaka Kawano, Hiroshi Miyamoto
Zitieren
APA
Sato, Y., Okamoto, K., Kawano, Y., Kasai, A., Kawaguchi, T., Sagawa, T., Sogabe, M., Miyamoto, H., & Takayama, T. (2023). Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives. Journal of Clinical Medicine, 12(14), 4646. https://doi.org/10.3390/jcm12144646
Vancouver
Sato Y, Okamoto K, Kawano Y, Kasai A, Kawaguchi T, Sagawa T, et al. Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives. Journal of Clinical Medicine. 2023;12(14):4646. doi:10.3390/jcm12144646
BibTeX
@article{Sato2023,
author = {Sato, Yasushi and Okamoto, Koichi and Kawano, Yutaka and Kasai, Akinari and Kawaguchi, Tomoyuki and Sagawa, Tamotsu and Sogabe, Masahiro and Miyamoto, Hiroshi and Takayama, Tetsuji},
title = {Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {14},
pages = {4646},
doi = {10.3390/jcm12144646}
}
EUVIMED